MohamadAHusseinMD

Oncology • Tampa, FL

Hematologic Oncology

Physician

Join to view full profile

Dr. Hussein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hussein's full profile

Already have an account?

Office
13330 Usf Laurel Dr
Tampa, FL 33612
Phone+1 813-974-2201

Fax+1 813-974-4325

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1986 - 1989
Cleveland Clinic FoundationResidency, Internal Medicine, 1985 - 1986
University of Mississippi Medical CenterResidency, Internal Medicine, 1983 - 1985
Ain Shams University Faculty of MedicineClass of 1981

Certifications & Licensure

OH State Medical License 1986 - 2026
FL State Medical License 2007 - 2025
MD State Medical License 1989 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Nov 01
Completed
Phase 2
Rituximab in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Nov 01
Completed
Phase 2
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2000 Mar 09
Completed
Phase 3
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma Start of enrollment: 2000 Apr 01
Terminated
Phase 3
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2002 Jun 01
Completed
Phase 2
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Withdrawn
Phase 2
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Aug 01
Terminated
Phase 2
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2006 Mar 01
Completed
Phase 2
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2016 Jul 11
Terminated
Phase 1
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) Start of enrollment: 2017 Jan 05
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

69 citations
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States In...
Madfhav V Dhodapkar, Mohamad A. Hussein, Erik Rasmussen, Alan Solomon, Richard A. Larson
Blood. 2004-12-01
90 citations
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
Mohamad A. Hussein, Mansoor N. Saleh, Farhad Ravandi, James R. Mason, Robert M. Rifkin
British Journal of Haematology. 2004-05-01
69 citations
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau
Clinical Cancer Research. 2017-08-01

Abstracts/Posters

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Mohamad A. Hussein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide Following Successful Skin Permeation StudiesJune 9th, 2021
Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of DirectorsSeptember 9th, 2020
ChemioCare Strengthens Its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad HusseinOctober 7th, 2019
Join now to see all

MohamadAHusseinMD

Dr. Hussein is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.